Get the Stockscreener App
21.14
2.63%
-0.57
After Hours:
21.14
Syndax Pharmaceuticals Inc stock is traded at $21.14, with a volume of 957.02K.
It is down -2.63% in the last 24 hours and up +2.03% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$21.71
Open:
$21.83
24h Volume:
957.02K
Relative Volume:
0.58
Market Cap:
$1.84B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-7.1419
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+4.91%
1M Performance:
+2.03%
6M Performance:
+62.99%
1Y Performance:
+42.26%
1-Day Range:
$20.95
$21.83
1-Week Range:
$20.25
$22.00
52-Week Range:
$8.58
$22.73
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
21.14 | 1.89B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
SNDX: Robust product growth, expanding indications, and disciplined spending set up a path to profitability - TradingView
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX) - Seeking Alpha
Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 17,159 Shares of Stock - MarketBeat
Keith Goldan Sells 3,410 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals CEO Metzger sells $360k in stock By Investing.com - Investing.com Canada
Candriam S.C.A. Raises Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. stock attractive for income investorsQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - mfd.ru
Setup Watch: Will Syndax Pharmaceuticals Inc benefit from green energy policiesMarket Trend Report & High Accuracy Trade Alerts - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Michael Metzger Sells 7,412 Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Sells 2,082 Shares of Stock - MarketBeat
Syndax Pharmaceuticals CEO sells $152,835 in SNDX stock By Investing.com - Investing.com Canada
Syndax Pharmaceuticals CEO sells $152,835 in SNDX stock - Investing.com
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit - The Manila Times
(SNDX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $28 - 富途牛牛
Keybank National Association OH Makes New $2.31 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Y Intercept Hong Kong Ltd Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. stock showing strong momentumWeekly Trend Summary & Reliable Entry Point Alerts - mfd.ru
Syndax’s Revumenib Solid-Tumor Trial Completion: What Investors Should Watch Next - TipRanks
Why is Syndax Pharmaceuticals Inc. stock going downPortfolio Update Summary & High Accuracy Trade Signal Alerts - mfd.ru
6 Analysts Assess Syndax Pharmaceuticals: What You Need To Know - Benzinga
Mizuho Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
SNDX: Mizuho Raises Price Target to $600 and Maintains 'Outperform' | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 9.5%What's Next? - MarketBeat
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating - MSN
Sector Gamma AS Acquires New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax’s Move to Commercial Stage With Two First-in-Class Drugs Might Change The Case For Investing In SNDX - Sahm
How (SNDX) Movements Inform Risk Allocation Models - Stock Traders Daily
Aug Summary: Is Syndax Pharmaceuticals Inc stock showing strong momentumJuly 2025 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Revuforj And Niktimvo Commercial Launch - Sahm
Several Syndax Pharmaceuticals Insiders Sell Shares Sending Potential Negative Signal - 富途牛牛
Aug Momentum: Is Syndax Pharmaceuticals Inc a defensive stockTreasury Yields & Weekly Return Optimization Plans - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Share Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory - Finviz
Expanded Global Access To Revuforj Could Be A Game Changer For Syndax Pharmaceuticals (SNDX) - Sahm
First Week of March 20th Options Trading For Syndax Pharmaceuticals (SNDX) - Nasdaq
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Last Year’s 62.5% Share Price Gain? - Yahoo Finance
Trading Systems Reacting to (SNDX) Volatility - Stock Traders Daily
Rate Hike: Will Syndax Pharmaceuticals Inc benefit from green energy policiesWeekly Profit Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Insider Buy: Will Syndax Pharmaceuticals Inc stock recover faster than peersJuly 2025 PreEarnings & AI Driven Stock Reports - Bộ Nội Vụ
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Expanded Revuforj Access And Recent Leukemia Progress - Sahm
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Market Trends: Can Syndax Pharmaceuticals Inc disrupt its industryPortfolio Return Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
New cancer drugs see rising demand as drugmaker shares 2025 sales - Stock Titan
Bearish Setup: Can Syndax Pharmaceuticals Inc disrupt its industryGDP Growth & Real-Time Sentiment Analysis - baoquankhu1.vn
Wall Street Zen Downgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to Sell - MarketBeat
Market Trends: Will Syndax Pharmaceuticals Inc. (1T3) stock benefit from Fed rate cutsTrade Risk Report & Expert Verified Movement Alerts - ulpravda.ru
Why Syndax Pharmaceuticals Inc. stock could outperform in 2025Recession Risk & Real-Time Buy Zone Alerts - Улправда
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):